TY - JOUR
T1 - Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning
T2 - Systematic Review and Recommendations from the EXTRIP Workgroup
AU - Berling, Ingrid
AU - King, Joshua D
AU - Shepherd, Greene
AU - Hoffman, Robert S
AU - Alhatali, Badria
AU - Lavergne, Valery
AU - Roberts, Darren M
AU - Gosselin, Sophie
AU - Wilson, Gabrielle
AU - Nolin, Thomas D
AU - Ghannoum, Marc
AU - EXTRIP workgroup
A2 - Høgberg, Lotte Christine Groth
N1 - Copyright © 2020 by the American Society of Nephrology.
PY - 2020/10
Y1 - 2020/10
N2 - BACKGROUND: Although chloroquine, hydroxychloroquine, and quinine are used for a range of medical conditions, recent research suggested a potential role in treating COVID-19. The resultant increase in prescribing was accompanied by an increase in adverse events, including severe toxicity and death. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup sought to determine the effect of and indications for extracorporeal treatments in cases of poisoning with these drugs.METHODS: We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.RESULTS: A total of 44 studies (three in vitro studies, two animal studies, 28 patient reports or patient series, and 11 pharmacokinetic studies) met inclusion criteria regarding the effect of extracorporeal treatments. Toxicokinetic or pharmacokinetic analysis was available for 61 patients (13 chloroquine, three hydroxychloroquine, and 45 quinine). Clinical data were available for analysis from 38 patients, including 12 with chloroquine toxicity, one with hydroxychloroquine toxicity, and 25 with quinine toxicity. All three drugs were classified as non-dialyzable (not amenable to clinically significant removal by extracorporeal treatments). The available data do not support using extracorporeal treatments in addition to standard care for patients severely poisoned with either chloroquine or quinine (strong recommendation, very low quality of evidence). Although hydroxychloroquine was assessed as being non-dialyzable, the clinical evidence was not sufficient to support a formal recommendation regarding the use of extracorporeal treatments for this drug.CONCLUSIONS: On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning.
AB - BACKGROUND: Although chloroquine, hydroxychloroquine, and quinine are used for a range of medical conditions, recent research suggested a potential role in treating COVID-19. The resultant increase in prescribing was accompanied by an increase in adverse events, including severe toxicity and death. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup sought to determine the effect of and indications for extracorporeal treatments in cases of poisoning with these drugs.METHODS: We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.RESULTS: A total of 44 studies (three in vitro studies, two animal studies, 28 patient reports or patient series, and 11 pharmacokinetic studies) met inclusion criteria regarding the effect of extracorporeal treatments. Toxicokinetic or pharmacokinetic analysis was available for 61 patients (13 chloroquine, three hydroxychloroquine, and 45 quinine). Clinical data were available for analysis from 38 patients, including 12 with chloroquine toxicity, one with hydroxychloroquine toxicity, and 25 with quinine toxicity. All three drugs were classified as non-dialyzable (not amenable to clinically significant removal by extracorporeal treatments). The available data do not support using extracorporeal treatments in addition to standard care for patients severely poisoned with either chloroquine or quinine (strong recommendation, very low quality of evidence). Although hydroxychloroquine was assessed as being non-dialyzable, the clinical evidence was not sufficient to support a formal recommendation regarding the use of extracorporeal treatments for this drug.CONCLUSIONS: On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning.
KW - COVID-19
KW - Chloroquine/poisoning
KW - Coronavirus Infections/complications
KW - Female
KW - Humans
KW - Hydroxychloroquine/poisoning
KW - Male
KW - Outcome Assessment, Health Care
KW - Pandemics/statistics & numerical data
KW - Pneumonia, Viral/diagnosis
KW - Poisoning/therapy
KW - Practice Guidelines as Topic
KW - Quinine/poisoning
KW - Renal Dialysis/methods
KW - Risk Assessment
KW - United States
U2 - 10.1681/ASN.2020050564
DO - 10.1681/ASN.2020050564
M3 - Journal article
C2 - 32963091
SN - 1046-6673
VL - 31
SP - 2475
EP - 2489
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 10
ER -